Amylyx Pharmaceuticals (AMLX) Stock Forecast: StockMap's 2-Week Call
AMLX stock forecast: StockMap's model leans Underperform on Amylyx Pharmaceuticals for the two weeks after the Nov 19 close, toward AMLX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.
Amylyx Pharmaceuticals last closed at $26.20, -1.58% on the session.
Against the IVW growth benchmark the position is +0.75% over the forecast window.
Amylyx Pharmaceuticals' market cap is $3.37B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -21 (too close to call).
Where AMLX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
4 daily calls for AMLX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Amylyx Pharmaceuticals in the 19th percentile on return on equity, where 100 is best.
Amylyx Pharmaceuticals is classified under Health Care / Pharmaceuticals.
StockMap tracks Amylyx Pharmaceuticals as the 34th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Amylyx Pharmaceuticals ranks 45th of 153 in the group, against a group median of -0.36.